(1R,2S,9R,10S,11R,15S,18R)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one

Base Information

• Chemical Name: (1R,2S,9R,10S,11R,15S,18R)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one
• CAS No.: 28957-04-2
• Molecular Formula: C₂₀H₂₈O₆
• Molecular Weight: 364.439
• Hs Code.: 29389090
• European Community (EC) Number: 631-100-8
• Mol file: 28957-04-2.mol

Synonyms:lasidonin;oridonin;oridonin, (1alpha,5alpha,6alpha,7beta,8beta,9alpha,10beta,13beta,14S)-isomer;oridonin, (1alpha,6beta,7alpha,11alpha)-isomer;oridonin, (1alpha,6beta,7alpha,11beta)-isomer

Chemical Property of (1R,2S,9R,10S,11R,15S,18R)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one

Chemical Property:

• Appearance/Colour: powder
• Vapor Pressure: 6.9E-17mmHg at 25°C
• Melting Point: 248-250 °C
• Refractive Index: 1.635
• Boiling Point: 599.8 °C at 760 mmHg
• PKA: 10.96±0.70(Predicted)
• Flash Point: 215 °C
• PSA: 107.22000
• Density: 1.42 g/cm³
• LogP: 0.37560
• Storage Temp.: 2-8°C
• Solubility.: DMSO: >20mg/mL
• XLogP3: 0.1
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 0
• Exact Mass: 364.18858861
• Heavy Atom Count: 26
• Complexity: 717

Purity/Quality:

more than 97% ^*data from raw suppliers

Oridonin ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn
• Statements: 40
• Safety Statements: 36/37-24/25

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C
• Isomeric SMILES: CC1(CC[C@@H]([C@@]23[C@@H]1[C@@H]([C@@](C45[C@H]2CCC([C@H]4O)C(=C)C5=O)(OC3)O)O)O)C
• Recent ClinicalTrials: Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI
• Description: Oridonin is a diterpenoid that has been found in R. rubescens and has anti-inflammatory and anticancer properties. It is an inhibitor of AKT1 and AKT2 (IC50s = 8.4 and 8.9 μM, respectively). Oridonin inhibits proliferation of KYSE70, KYSE410, and KYSE450 esophageal cancer cells in a dose-dependent manner, halts the cell cycle at the G2/M phase, and induces apoptosis when used at a concentration of 20 μM. It decreases the expression of cleaved poly(ADP-ribose) polymerase (PARP), caspase-3, caspase-7, and Bims and the protein levels of phosphorylated AKT and reduces AKT activity. Oridonin reduces tumor growth in patient-derived mouse tumor models when administered at doses of 40 and 160 mg/kg. Oridonin is also an inhibitor of NLRP3 inflammasome assembly and activation. It inhibits inflammation in wild-type, but not Nlrp3-/-, mice in a model of high-fat diet-induced type 2 diabetes when administered at a dose of 3 mg/kg.
• Uses: Oridonin is an effective anticancer agent due to its ability to inhibit proliferation and induce apoptosis of human osteosarcoma cells. Blocks Wnt/β-catenin signalling.